Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective November 6, 2022, Alex Wylie resigned as Interim Chairman, Director,
Interim Chief Executive Officer and Chief Financial Officer of the Registrant
and as Interim Chairman, Director, Interim Chief Executive Officer and Chief
Financial Officer of its wholly owned Canadian subsidiary ("Instadose Canada").
Mr. Wylie will not hold any officer or director positions at the Registrant or
Instadose Canada following his resignation.
Effective November 6, 2022, Ann Barnes resigned as Director of the Registrant
and as Director of its wholly owned Canadian subsidiary ("Instadose Canada").
Ms. Barnes will not hold any officer or director positions at the Registrant or
Instadose Canada following her resignation.
The Registrant accepted the resignation of Alex Wylie from the Board of
Directors and all management positions he had held with the Registrant. The
Registrant also accepted the resignation of Ann Barnes from the Board of
Directors of the Registrant.
Antonio Franchino will succeed Mr. Wylie as Chairman and Chief Executive Officer
of the Registrant.
The Registrant's Board of Directors initiated a process to find a permanent
Chairman and Chief Executive Officer of the Registrant commencing in January
2022. The Board of Directors believes that Mr. Franchino is a highly qualified
leader to navigate Instadose through its next stage of growth as he has
significant past experience in a Chairman role and through his extensive legal
training. Mr. Franchino is based in Luxembourg which is strategic for Instadose
as it transitions the majority of its operations to Europe.
The Board of Directors would like to thank Mr. Wylie and Ms. Barnes for their
initiatives to reposition the Company to Europe and to find a highly reputable
replacement to succeed them in the business as it focuses on its next stage of
growth.
A copy of the Curriculum Vitae for Mr. Franchino is attached hereto as Exhibit
16.1 to this Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
16.1 Curriculum Vitae Antonio Franchino
104 Cover Page Interactive Data File (embedded within the Inline XBRL
Document)
2
© Edgar Online, source Glimpses
INSTADOSE PHARMA CORP. 
